Realta Life Sciences raised an additional $40 million in the final tranche of its Series A, bringing total funding to more than $150 million. The company is developing a treatment for hypoxic ischemic encephalopathy (HIE), a neonatal condition driven by oxygen deprivation and reduced blood flow around birth. The raise was structured through a mix of mission-driven investors and a family-office model, according to the report. The company’s latest funding arrives as clinical progress in neonatal neuroprotection continues to draw capital. For developers, the funding underscores how investors are prioritizing translational programs targeting time-critical perinatal injuries with clear unmet need.